Press releaseGlobe Newswire
Candel Therapeutics
CADL · NASDAQ
$8.64+$0.43 (+5.24%)TodayMarket closed ·
Prev close $8.21
Latest news
- Press releaseGlobe Newswire
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
- Press releaseGlobe Newswire
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
- Press releaseGlobe Newswire
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
- Press releaseGlobe Newswire
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
- Press releaseGlobe Newswire
Candel Therapeutics to Present at September Investor Conferences
- Press releaseGlobe Newswire
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Press releaseGlobe Newswire
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
- Press releaseGlobe Newswire
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
- Press releaseGlobe Newswire
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
- NewsNabaparna Bhattacharya
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
- News
Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate
- Press releaseGlobe Newswire
Candel Therapeutics to Present at Upcoming Investor Conferences
- Press releaseGlobe Newswire
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
- NewsEvette Mitkov
Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsRishabh Mishra
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)
- NewsAvi Kapoor
Akamai Technologies, Inseego, Ardelyx And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsVandana Singh
Why Is Candel Therapeutics Stock Falling Friday?
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday
- Press releaseGlobe Newswire
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Press releasePRNewswire
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
- Press releaseGlobe Newswire
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
- Press releaseGlobe Newswire
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
- NewsAvi Kapoor
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
- News
Candel Therapeutics Q1 EPS $0.13 Beats $(0.21) Estimate
- Press releaseGlobe Newswire
Candel Therapeutics to Present at Upcoming Investor Conferences
- NewsAvi Kapoor
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- News
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
- News
10 Health Care Stocks Whale Activity In Today's Session
- NewsAvi Kapoor
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
- News
Market-Moving News for December 11th
- Press releaseGlobe Newswire
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
- Press releaseGlobe Newswire
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
- Press releaseGlobe Newswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Press releasePRNewswire
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
- NewsMichael Juliano
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.